Search details
1.
Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor.
Mol Pharmacol
; 103(3): 176-187, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36804203
2.
Ensemble Docking Approach to Mitigate Pregnane X Receptor-Mediated CYP3A4 Induction Risk.
J Chem Inf Model
; 63(1): 173-186, 2023 01 09.
Article
in English
| MEDLINE | ID: mdl-36473234
3.
The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers.
J Pharmacol Exp Ther
; 380(3): 143-152, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34893551
4.
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial.
Mov Disord
; 37(3): 513-524, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34859493
5.
Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.
Nat Chem Biol
; 16(3): 240-249, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32080630
6.
Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor.
Mol Pharmacol
; 94(4): 1232-1245, 2018 10.
Article
in English
| MEDLINE | ID: mdl-30111649
7.
An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis.
J Pharmacol Exp Ther
; 360(1): 117-128, 2017 Jan.
Article
in English
| MEDLINE | ID: mdl-27811173
8.
The dopamine D1 receptor positive allosteric modulator, DETQ, improves cognition and social interaction in aged mice and enhances cortical and hippocampal acetylcholine efflux.
Behav Brain Res
; 459: 114766, 2024 02 29.
Article
in English
| MEDLINE | ID: mdl-38048913
9.
Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate.
Psychopharmacology (Berl)
; 240(5): 1033-1048, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36961560
10.
Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: a microdialysis study.
J Neurosci Res
; 90(3): 588-96, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-22038504
11.
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease.
Clin Pharmacol Drug Dev
; 11(3): 324-332, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34664427
12.
Synthesis and Preclinical Characterization of LY3154885, a Human Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Nonclinical Drug-Drug Interaction Risk Profile.
J Med Chem
; 65(5): 3786-3797, 2022 03 10.
Article
in English
| MEDLINE | ID: mdl-35175768
13.
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
J Pharmacol Exp Ther
; 336(1): 165-77, 2011 Jan.
Article
in English
| MEDLINE | ID: mdl-20947638
14.
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects.
Clin Pharmacol Drug Dev
; 10(4): 393-403, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33029934
15.
Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Pharmacol Ther
; 120(3): 317-32, 2008 Dec.
Article
in English
| MEDLINE | ID: mdl-18805436
16.
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
J Pharmacol Exp Ther
; 331(3): 1126-36, 2009 Dec.
Article
in English
| MEDLINE | ID: mdl-19755662
17.
Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders.
Adv Pharmacol
; 86: 273-305, 2019.
Article
in English
| MEDLINE | ID: mdl-31378255
18.
The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice.
Behav Brain Res
; 361: 139-150, 2019 04 01.
Article
in English
| MEDLINE | ID: mdl-30521930
19.
Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor.
J Med Chem
; 62(19): 8711-8732, 2019 10 10.
Article
in English
| MEDLINE | ID: mdl-31532644
20.
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
J Pharmacol Exp Ther
; 326(1): 209-17, 2008 Jul.
Article
in English
| MEDLINE | ID: mdl-18424625